Abstract: Controlled studies demonstrate that methods using soy related peptides inhibit H3 acetylation, reduce expression of HMG CoA reductase and increase LDL receptor and Sp1 expression in mammals. The present disclosure is generally directed to using lunasin peptides and/or lunasin peptide derivatives to 1) inhibit H3 acetylation, 2) reduce expression of HMG CoA reductase, 3) increase LDL receptor expression or 4) increase Sp1 expression in a mammal. In at least one exemplary embodiment of the present disclosure, an effective amount of lunasin peptides or lunasin peptide derivatives and one or more enzyme inhibitors is provided to a mammal to 1) inhibit H3 acetylation, 2) reduce expression of HMG CoA reductase, 3) increase LDL receptor expression or 4) increase Sp1 expression in a mammal.
Abstract: Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes. In particular, quinacrine mustard is used to inactivate pathogens in red cell compositions with retention of red cell function.
Type:
Grant
Filed:
November 14, 1994
Date of Patent:
November 25, 1997
Assignee:
Cerus Corporation
Inventors:
Susan Wollowitz, David Cook, Aileen Nerio
Abstract: A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
November 4, 1997
Assignee:
Cerus Corporation
Inventors:
David P. Hearst, George D. Cimino, John E. Hearst, Stephen T. Isaacs
Abstract: The present invention contemplates methods of decontaminating human fluids prior to processing in the clinical laboratory. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
September 9, 1997
Assignee:
Carus Corporation
Inventors:
Peter G. Carroll, Stephen T. Isaacs, George D. Cimino
Abstract: The present invention contemplates methods of decontaminating human fluids prior to processing in the clinical laboratory. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.
Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.
Type:
Grant
Filed:
May 31, 1995
Date of Patent:
August 5, 1997
Assignee:
Cerus Corporation
Inventors:
Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
Abstract: Synthesis of 4,8-dialkyl-4'-bromomethyl-5'-methylpsoralen and 4,8-dialkyl-5'-bromomethyl-4'-methylpsoralen compounds useful as intermediates.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
April 29, 1997
Assignee:
Cerus Corporation
Inventors:
Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans P. Spielmann, Aileen Nerio
Abstract: Intravenous administration of 8-methoxypsoralen is disclosed, and more specifically intravenous administration of 8-methoxypsoralen-blood preparations, including platelets. Random donor platelet bags are treated, stored and pooled prior to transfusion.
Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.
Type:
Grant
Filed:
November 14, 1994
Date of Patent:
January 14, 1997
Assignee:
Cerus Corporation
Inventors:
Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans P. Spielmann, Aileen Nerio
Abstract: The present invention contemplates methods of decontaminating human fluids prior to processing in the clinical laboratory. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
December 10, 1996
Assignee:
Steritech, Inc.
Inventors:
Peter G. Carroll, Stephen T. Isaacs, George D. Cimino
Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.
Type:
Grant
Filed:
May 31, 1995
Date of Patent:
November 26, 1996
Assignee:
Steritech, Inc.
Inventors:
Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans P. Spielmann
Abstract: A quality control assay to verify adequate treatment of blood product following decontamination with furocoumarins and light. The methods involve measuring the inhibition of template-dependent enzymatic synthesis of nucleic acid following the addition of compounds that add covalently to nucleic acid.
Abstract: Novel compounds for photodecontaminating biological material which are compatible with clinical testing, in that they do not interfere with serum analytes.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
September 24, 1996
Assignee:
Steritech, Inc.
Inventors:
David Cook, Susan Wollowitz, Aileen Nerio
Abstract: Psoralen compounds are synthesized which have substitutions on the 4,4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
September 17, 1996
Assignee:
Steritech, Inc.
Inventors:
Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans P. Spielmann, Aileen Nerio
Abstract: The present invention contemplates methods of decontaminating human fluids prior to processing in the clinical laboratory. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.
Type:
Grant
Filed:
June 3, 1994
Date of Patent:
September 17, 1996
Assignee:
Steritech, Inc.
Inventors:
Peter G. Carroll, Stephen T. Isaacs, George D. Cimino
Abstract: Method useful for solving the problem of contamination of protein with nucleic acid. Rendering amplifiable contaminating nucleic acid in enzyme preparations substantially unamplifiable prior to use of the enzyme.
Type:
Grant
Filed:
November 20, 1992
Date of Patent:
July 2, 1996
Assignee:
Steritech, Inc.
Inventors:
John W. Tessman, George D. Cimino, Stephen T. Isaacs, John E. Hearst
Abstract: Methods and compositions are described for treating contaminants in material intended for in vivo use, and in particular blood and blood products for human use. Compositions of synthetic media are described which optimize conditions for inactivation of contaminants in blood cell preparations, using 8-methoxypsoralen, prior to long term storage and transfusion.
Type:
Grant
Filed:
March 7, 1994
Date of Patent:
January 9, 1996
Assignee:
Steritech, Inc.
Inventors:
Lily Lin, Lawrence Corash, Stephen Isaacs, George Cimino
Abstract: Synthetic media formulations are disclosed for use with blood preparations intended for in vivo use, including synthetic media formulations to be employed in conjunction with the photodecontamination of platelets using 8-methoxypsoralen.
Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.
Type:
Grant
Filed:
June 28, 1993
Date of Patent:
March 21, 1995
Assignee:
Steritech, Inc.
Inventors:
Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans P. Spielmann
Abstract: Methods for measuring pathogen inactivation, and in particular, methods for measuring pathogen inactivation in blood and blood products after photochemical decontamination. The methods involve measuring the inhibition of template-dependent enzymatic synthesis of nucleic acid following the addition of compounds that add covalently to nucleic acid.